SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : The Financial Collapse of 2001 Unwinding

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cogito Ergo Sum who wrote (4964)3/25/2020 10:09:03 PM
From: Elroy Jetson  Read Replies (1) of 13794
 
The 40 person French study did not show any clinical improvement in any patients or a shorter duration or severity of illness in patients taking hydroxychloroquine.

The French study merely showed a lower viral count in the sinuses, so hydroxychloroquine may be a promising way to make it harder to detect a Covid infection.

The only reason anyone thought hydroxychloroquine provided any benefit was this badly designed 40 person study in France.

.

The chance that a 3,000 person study would reveal a significant benefit from hydroxychloroquine is vanishingly small.

Our non-profit running trials of "treatments" for HIV in the 1990s found many, many false signals like this.

Often true-believers of a 'therapy' would fund larger trials themselves only to be disappointed, or even more bizarre they would continue to believe in their 'therapy' even after the larger trial showed no benefit.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext